Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Heart Failure

In brief

This trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood Stasis).

Key facts

Study ID

NCT07687186

Run by

Tasly Pharmaceutical Group Co., Ltd

People needed

636

Starts

2026-06-22

Expected to finish

2028-06-22

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects aged ≥ 18 years and ≤80 years when signing the informed consent form.
• Conformed to the diagnostic criteria of coronary heart disease and chronic heart failure.
• Conformed to the TCM syndrome differentiation standard of chronic heart failure syndrome of Qi deficiency and blood stasis.
• NYHA Functional Classification Ⅱ-Ⅲ.
• Left ventricular ejection fraction (LVEF) < 45% (modified two-plane Simpson method).
• Received standardized drug therapy for chronic heart failure at least 2 weeks before randomization without adjustment of dose, and did not receive intravenous therapy (vasoactive drugs, diuretics) within 2 weeks.
• Voluntarily participate in the clinical trial, sign the informed consent form, and be able to understand and comply with the trial procedures.

You may not qualify if…

• Heart failure caused by other cardiovascular diseases, such as infectious endocarditis, cardiac amyloidosis, genetic abnormalities (genetic factors related to hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy), valve and cardiac structure abnormalities (moderate or above aortic valve stenosis, other severely narrowed or incompetent heart valves, congenital heart disease), constrictive pericarditis, moderate or large pericardial effusion.
• Heart failure caused by other non-cardiovascular diseases, such as severe infection, autoimmune diseases, tumor metastasis or infiltration, pulmonary heart disease, primary pulmonary hypertension, secondary severe pulmonary hypertension, kidney diseases, liver diseases, cardiac toxic injury (cardiotoxic drugs such as anti-tumor drugs, alcoholic cardiomyopathy).
• Within 3 months before receiving the investigational drug, had acute myocardial infarction, undergone revascularization [percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)] treatment, undergone left ventricular assist device [cardiac resynchronization therapy (CRT), implantable cardioverter defibrillator (ICD), etc.] treatment, undergone cardiac surgery (left ventricular reconstruction, heart transplantation, etc.) treatment, had acute cerebrovascular events (acute ischemic stroke, cerebral hemorrhage, transient ischemic attack).
• Planned to undergo revascularization (PCI, CABG, etc.) or left ventricular assist device (CRT, ICD, etc.) treatment, or other cardiac surgery during the trial.
• Had severe, progressive, or uncontrolled diseases, including but not limited to immune system, endocrine system, blood system, urinary system, liver and gallbladder system, respiratory system, nervous system, mental system, cardiovascular system, gastrointestinal system or infectious diseases, malignant tumors, etc.
• Had uncontrolled hypertension (after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg), or had hypotension (systolic blood pressure < 80 mmHg and/or diastolic blood pressure < 50 mmHg).
• Severe arrhythmias such as ventricular tachycardia, second-degree type II or above sinus or atrioventricular conduction block without pacemaker treatment.
• Abnormal liver function tests [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of the normal value of the laboratory in this center], or abnormal renal function tests [serum creatinine (Cr) > 1.5 times the upper limit of the normal value of the laboratory].
• Glycated hemoglobin (HbA1c) ≥ 9.0%.
• Hemoglobin (Hb) < 90 g/L.
• Serum potassium concentration > 5.5 mmol/L.
• Need to take anticoagulants, dose stable for less than 1 month, or INR > 3.0.
• Need to take antiplatelet drugs, dose stable for less than 1 month, and platelets lower than the lower limit of the normal value.
• Allergic to the Chinese medicine formula of Qishen YiQi (QSYQ) Dripping Pills (Astragalus membranaceus, Salvia miltiorrhiza, Panax notoginseng, and Dalbergia odorifera), or allergic to other Chinese medicines with the same ingredients or the same therapeutic functions.
• Within 2 weeks before randomization, had received drugs affecting exercise tolerance assessment (such as trimetazidine, renozine, coenzyme Q10, levocarnitine, and androgens) or Chinese medicine preparations with the same ingredients or the same therapeutic functions.
• Had absolute contraindications for the 6-minute walk test or was unable to complete the 6-minute walk test.
• Had participated in other interventional drug clinical trials within 1 month before screening.
• Pregnant or lactating women, or had a pregnancy plan or could not take effective contraceptive measures from the screening period to the end of the trial and within 1 month after the last administration.
• Any other circumstances where other researchers deem it inappropriate for a participant to take part in the trial, such as if the participant has potential issues with compliance, is unable to complete all the examinations and evaluations as per the protocol requirements, or if there are uncontrollable risks associated with participating in the trial.

Where it is running

• The First Affiliated Hospital of Guangzhou University of Chinese Medicine — Guangzhou, Guangdong, China (enrolling)
• Anhui Suzhou Municipal Hospital — Suzhou, Anhui, China
• The First Hospital of Hebei Medical University — Shijiazhuang, Hebei, China
• Fujian Provincial Hospital — Fuzhou, Fujian, China
• Gansu Provincial Hospital — Lanzhou, Gansu, China
• The Second Hospital of Lanzhou University — Lanzhou, Gansu, China
• Qingyang People's Hospital — Qingyang, Gansu, China
• Guangzhou University of Chinese Medicine Dongguan Hospital (Dongguan Hospital of Traditional Chinese Medicine) — Dongguan, Guangdong, China
• Guangzhou Red Cross Hospital — Guangzhou, Guangdong, China
• Heilongjiang Provincial Hospital — Harbin, Heilongjiang, China
• Liuzhou People's Hospital — Liuzhou, Guangxi, China
• The First Affiliated Hospital of Guangxi University of Chinese Medicine — Nanning, Guangxi, China
• The First People's Hospital of Yulin — Yulin, Guangxi, China
• Hebei Provincial Hospital of Traditional Chinese Medicine — Shijiazhuang, Hebei, China
• Xiyuan Hospital, China Academy of Chinese Medical Sciences — Beijing, Beijing Municipality, China
• Affiliated Hospital of North China University of Science and Technology — Tangshan, Hebei, China
• The Second Affiliated Hospital of Xingtai Medical College — Xingtai, Hebei, China
• Xingtai Central Hospital — Xingtai, Hebei, China
• The First Affiliated Hospital of Hebei North University — Zhangjiakou, Hebei, China
• Daqing People's Hospital — Daqing, Heilongjiang, China
• The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) — Hefei, Anhui, China
• Hebi People's Hospital — Hebi, Henan, China
• Huaihe Hospital of Henan University — Kaifeng, Henan, China
• The First Affiliated Hospital of Henan University — Kaifeng, Henan, China
• Bozhou People's Hospital — Bozhou, Anhui, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.